Rojymon Jacob

Target localization for post-prostatectomy patients using CT and ultrasound image guidance.

We conducted a study comparing B‐mode acquisition and targeting (BAT) ultrasound alignments based on CT data in the postoperative setting. CT scans were obtained with a Primatom CT‐on‐rails on nine patients. Two CT scans were obtained each week, while setup error was minimized by BAT ultrasounds. For the first three patients, a direct comparison was performed. For the next six patients, a template based on the shifts from the week 1 CT during treatment was used for subsequent setup. Comparison of isocenter shifts between the BAT ultrasound and CT was made by the difference, absolute difference, and improvement (using CT alignments as the reference technique). A total of 90 image comparisons were made. The average interfraction motion was 3.2 mm in the lateral, 3.0 mm in the longitudinal, and 5.1 mm in the AP direction. The results suggest that the CT‐based ultrasound templates can improve the localization of the prostate bed when the initial displacements are greater than 4 mm. For initial displacements smaller than 4 mm, the technique neither improved nor worsened target localization. However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements. PACS numbers: 87.53.‐j, 87.53.Kn, 87.53.Xd

Daily target localization for prostate patients based on 3D image correlation

There are several localization techniques that have been used for prostate treatment. Recently, the potential use of a variety of CT-based equipment in the treatment room has been discussed. The goal of our study was to develop an automated procedure for daily treatment table shift calculation based on two CT data sets: simulation CT data and localization CT data. The method suggested in this study is a 3D image cross-correlation of small regions of interest (ROI) within the two data sets. The relative position of the two ROIs with respect to each other is determined by the maximum value of the normalized cross-correlation function, calculated for all possible relative locations of the two ROIs. After the best match is found the shifts are given by the vector connecting the treatment isocentre and the planning isocentre (both determined by the radio opaque fiducial markers on the patients skin). The results have been compared with shifts calculated through manual fusion. The shift differences, averaged over 17 statistically independent shift calculations, are less then 1 mm in the lateral and longitudinal directions, and about 1 mm in the AP direction. The impact of image noise on the performance of the algorithm has been tested. The results show that the algorithm accurately adjusts for target positional changes even with Gaussian noise levels as high as 20% inserted.

Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.

The focus of this work is the dosimetric impact of multileaf collimator (MLC) leaf width on the treatment of prostate cancer with intensity‐modulated radiation therapy (IMRT). Ten patients with prostate cancer were planned for IMRT delivery using two different MLC leaf widths—4 mm and 10 mm— representing the Radionics micro‐multileaf collimator (mMLC) and Siemens MLC, respectively. Treatment planning was performed on the XKnifeRT2 treatment‐planning system (Radionics, Burlington, MA). All beams and optimization parameters were identical for the mMLC and MLC plans. All the plans were normalized to ensure that 95% of the planning target volume (PTV) received 100% of the prescribed dose. The differences in dose distribution between the two different plans were assessed by dose–volume histogram (DVH) analysis of the target and critical organs. We specifically compared the volume of rectum receiving 40 Gy (V40), 50 Gy (V50), 60 Gy (V60), the dose received by 17% and 35% of rectum (D17 and D35), and the maximum dose to 1 cm3 of the rectum for a prescription dose of 74 Gy. For the urinary bladder, the dose received by 25% of bladder (D25), V40, and the maximum dose to 1 cm3 of the organ were recorded. For PTV we compared the maximum dose to the “hottest” 1 cm3 (Dmax1cm3) and the dose to 99% of the PTV (D99). The dose inhomogeneity in the target, defined as the ratio of the difference in Dmax1cm3 and D99 to the prescribed dose, was also compared between the two plans. In all cases studied, significant reductions in the volume of rectum receiving doses less than 65 Gy were seen using the mMLC. The average decrease in the volume of the rectum receiving 40 Gy, 50 Gy, and 60 Gy using the mMLC plans was 40.2%, 33.4%, and 17.7%, respectively, with p<0.0001 for V40 and V50 and p<0.012 for V60. The mean dose reductions for D17 and D35 for the rectum using the mMLC were 20.4% (p<0.0001) and 18.3% (p<0.0002), respectively. There were consistent reductions in all dose indices studied for the bladder. The target dose inhomogeneity was improved in the mMLC plans by an average of 29%. In the high‐dose range, there was no significant difference in the dose deposited in the “hottest” 1 cm3 of the rectum between the two plans for all cases (p>0.78). In conclusion, the use of the mMLC for IMRT of the prostate resulted in significant improvement in the DVH parameters of the prostate and critical organs, which may improve the therapeutic ratio. PACS number: 87.53.Tf